"document"	"claim label"	"claim text"	"method"	"relationship"	"drug1"	"drug2"	"precipitant"	"enzyme"	"particitants"	"participants text"	"drug1 dose"	"drug1 formulation"	"drug1 duration"	"drug1 regimens"	"drug1 dose text"	"drug2 dose"	"drug2 formulation"	"drug2 duration"	"drug2 regimens"	"drug2 dose text"	"auc"	"auc type"	"auc direction"	"auc text"	"cmax"	"cmax type"	"cmax direction"	"cmax text"	"cl"	"cl type"	"cl direction"	"cl text"	"halflife"	"halflife type"	"halflife direction"	"halflife text"
"http://localhost/dbmiannotator/PMC2764168.html"	"TPV/r_interact with_rosuvastatin"	"With TPV/r coadministration, the GM AUC for rosuvastatin was 38.6 ng·h/ml, a 37% increase compared with that of rosuvastatin alone (P = 0.0006) (Fig. ​(Fig.11 and ​and2).2)."	"DDI clinical trial"	"interact with"	"TPV/r"	"rosuvastatin"	"drug1"	""	"29"	"Of the 29 subjects (5 women, 24 men), 16 evaluable subjects completed the study."	"500/200"	"Oral"	"11"	"BID"	"This was a prospective, open-label, single-arm, inpatient, steady-state PK study. Subjects received a single 10-mg dose of rosuvastatin on day 1, followed by tipranavir 500 mg-ritonavir 200 mg twice daily for 11 days (days 3 to 13), with a single 10-mg dose of rosuvastatin given on day 12."	"10"	"Oral"	"1"	"SD"	"This was a prospective, open-label, single-arm, inpatient, steady-state PK study. Subjects received a single 10-mg dose of rosuvastatin on day 1, followed by tipranavir 500 mg-ritonavir 200 mg twice daily for 11 days (days 3 to 13), with a single 10-mg dose of rosuvastatin given on day 12."	"37"	"increase"	"percent"	"With TPV/r coadministration, the GM AUC for rosuvastatin was 38.6 ng·h/ml, a 37% increase compared with that of rosuvastatin alone (P = 0.0006) (Fig. ​(Fig.11 and ​and2).2)."	"123"	"increase"	"percent"	"The GM Cmax for rosuvastatin was 5.78 ng/ml with TPV/r coadministration, a 123% increase compared with that of rosuvastatin alone (P < 0.001) (Table ​(Table1).1)"	"27"	"decrease"	"percent"	"Rosuvastatin clearance (CL) also was decreased by 27% with TPV/r coadministration; this resulted in a significant increase in plasma t1/2 (20.6 h versus 9.01 h; P < 0.001)"	"2.29"	"increase"	"fold"	"Rosuvastatin clearance (CL) also was decreased by 27% with TPV/r coadministration; this resulted in a significant increase in plasma t1/2 (20.6 h versus 9.01 h; P < 0.001)"
"http://localhost/dbmiannotator/PMC2764168.html"	"TPV/r_interact with_atorvastatin"	"TPV/r increased the dose-adjusted atorvastatin AUC0-∞ and Cmax by approximately ninefold (Table ​(Table2;2; Fig. ​Fig.33 and ​and4).4)."	"DDI clinical trial"	"interact with"	"TPV/r"	"atorvastatin"	"drug1"	""	"23"	"Twenty-three subjects (11 men, 12 women) were recruited into this study"	"500/200"	"Oral"	"7"	"BID"	"The single-dose PKs of atorvastatin, orthohydroxy atorvastatin, and parahydroxy atorvastatin were assessed on day 1 after ingestion of 40 mg of atorvastatin alone. From days 14 to 21, subjects received TPV/r 500 mg/200 mg twice daily."	"40"	"Oral"	"1"	"SD"	"The single-dose PKs of atorvastatin, orthohydroxy atorvastatin, and parahydroxy atorvastatin were assessed on day 1 after ingestion of 40 mg of atorvastatin alone"	"9"	"increase"	"fold"	"TPV/r increased the dose-adjusted atorvastatin AUC0-∞ and Cmax by approximately ninefold (Table ​(Table2;2; Fig. ​Fig.33 and ​and4).4)."	"9"	"increase"	"fold"	"TPV/r increased the dose-adjusted atorvastatin AUC0-∞ and Cmax by approximately ninefold (Table ​(Table2;2; Fig. ​Fig.33 and ​and4).4)."	"undefined"	"undefined"	"undefined"	"undefined"	"unchanged"	""	""	"As both apparent CL/F and apparent V/F were decreased almost proportionally, there was no effect on the t1/2 of atorvastatin"
"http://localhost/dbmiannotator/PMC3769672.html"	"ketoconazole_interact with_rivaroxaban "	"Co-administration with steady-state ketoconazole significantly increased the plasma concentrations of a single dose of rivaroxaban 10 mg compared with rivaroxaban alone. The mean AUC increased by 82% (90% CI 59%, 108%) and the mean Cmax increased by 53% (90% CI 27%, 85%). The total (apparent) body clearance of drug from plasma (CL/F) of rivaroxaban was significantly reduced by a mean of 45% (90% CI −52%, −37%) with combined vs. rivaroxaban alone."	"DDI clinical trial"	"interact with"	"ketoconazole"	"rivaroxaban "	"drug1"	""	"12"	"In the ketoconazole 200 mg study, 12 subjects were enrolled. All completed the study and were included in the safety and pharmacokinetic analyses. Their mean age was 33 years (range 24-41 years) and their mean weight was 86.4 ± 9.2 kg."	"200"	"Oral"	"4"	"QD"	"The initial ketoconazole interaction study investigated the potential interaction between a single dose of rivaroxaban and steady-state ketoconazole 200 mg once daily. In this open label, two way crossover study, subjects were randomized to receive a single dose of rivaroxaban 10 mg, alone or with ketoconazole (4 days of oral ketoconazole 200 mg once daily with rivaroxaban given on day 4). Rivaroxaban was given under fasting conditions and ketoconazole was given with food, except when co-administered with rivaroxaban."	"10"	"Oral"	"1"	"SD"	"The initial ketoconazole interaction study investigated the potential interaction between a single dose of rivaroxaban and steady-state ketoconazole 200 mg once daily. In this open label, two way crossover study, subjects were randomized to receive a single dose of rivaroxaban 10 mg, alone or with ketoconazole (4 days of oral ketoconazole 200 mg once daily with rivaroxaban given on day 4). Rivaroxaban was given under fasting conditions and ketoconazole was given with food, except when co-administered with rivaroxaban."	"82"	"increase"	"percent"	"Co-administration with steady-state ketoconazole significantly increased the plasma concentrations of a single dose of rivaroxaban 10 mg compared with rivaroxaban alone. The mean AUC increased by 82% (90% CI 59%, 108%) and the mean Cmax increased by 53% (90% CI 27%, 85%). The total (apparent) body clearance of drug from plasma (CL/F) of rivaroxaban was significantly reduced by a mean of 45% (90% CI −52%, −37%) with combined vs. rivaroxaban alone."	"53"	"increase"	"percent"	"Co-administration with steady-state ketoconazole significantly increased the plasma concentrations of a single dose of rivaroxaban 10 mg compared with rivaroxaban alone. The mean AUC increased by 82% (90% CI 59%, 108%) and the mean Cmax increased by 53% (90% CI 27%, 85%). The total (apparent) body clearance of drug from plasma (CL/F) of rivaroxaban was significantly reduced by a mean of 45% (90% CI −52%, −37%) with combined vs. rivaroxaban alone."	"45"	"decrease"	"percent"	"The total (apparent) body clearance of drug from plasma (CL/F) of rivaroxaban was significantly reduced by a mean of 45% (90% CI −52%, −37%) with combined vs. rivaroxaban alone."	"undefined"	"undefined"	"undefined"	"undefined"
"http://localhost/dbmiannotator/PMC3769672.html"	"ketoconazole_interact with_rivaroxaban "	"Co-administration with steady-state ketoconazole significantly increased the plasma concentrations of a single dose of rivaroxaban 10 mg compared with rivaroxaban alone. The mean AUC increased by 82% (90% CI 59%, 108%) and the mean Cmax increased by 53% (90% CI 27%, 85%). The total (apparent) body clearance of drug from plasma (CL/F) of rivaroxaban was significantly reduced by a mean of 45% (90% CI −52%, −37%) with combined vs. rivaroxaban alone."	"DDI clinical trial"	"interact with"	"ketoconazole"	"rivaroxaban "	"drug1"	""	"20"	"In the ketoconazole 200 mg study, 12 subjects were enrolled. All completed the study and were included in the safety and pharmacokinetic analyses. Their mean age was 33 years (range 24-41 years) and their mean weight was 86.4 ± 9.2 kg. In the ketoconazole 400 mg study, a total of 20 subjects were enrolled. All completed the study and, therefore, were valid for the safety and pharmacokinetic analyses. Their mean age was 34.2 years (range 22-45 years) and their mean weight was 82.9 ± 10.9 kg."	"400"	"Oral"	"5"	"QD"	"After completion of this study, a publication suggested that ketoconazole 400 mg may lead to higher inhibition of CYP 34, which prompted a second study investigating the maximum extent of the potential interaction between steady-state rivaroxaban and steady-state ketoconazole 400 mg once daily. This was a non-randomized, open label study in which subjects received oral rivaroxaban 10 mg once daily alone for 5 days, with concomitant ketoconazole 400 mg once daily for a further 5 days. All study drugs were administered with food."	"10"	"Oral"	"5"	"QD"	"After completion of this study, a publication suggested that ketoconazole 400 mg may lead to higher inhibition of CYP 34, which prompted a second study investigating the maximum extent of the potential interaction between steady-state rivaroxaban and steady-state ketoconazole 400 mg once daily. This was a non-randomized, open label study in which subjects received oral rivaroxaban 10 mg once daily alone for 5 days, with concomitant ketoconazole 400 mg once daily for a further 5 days. All study drugs were administered with food."	"158"	"increase"	"percent"	"Co-administration with ketoconazole 400 mg significantly increased rivaroxaban plasma concentrations (Figure 1A). The mean AUC for the actual dose interval (AUCτ) was increased by 158% (90% CI 136%, 182%) and the mean Cmax by 72% (90% CI 61%, 83%) with the combination compared with rivaroxaban alone (Table 2). The mean CL/F was significantly decreased by 61% (90% CI −65%, −58%) with the combination of drugs, and clearance by active renal secretion (CLRS) was also significantly reduced by a mean of 44% (90% CI −50%, −32%)."	"72"	"increase"	"percent"	"Co-administration with ketoconazole 400 mg significantly increased rivaroxaban plasma concentrations (Figure 1A). The mean AUC for the actual dose interval (AUCτ) was increased by 158% (90% CI 136%, 182%) and the mean Cmax by 72% (90% CI 61%, 83%) with the combination compared with rivaroxaban alone (Table 2). The mean CL/F was significantly decreased by 61% (90% CI −65%, −58%) with the combination of drugs, and clearance by active renal secretion (CLRS) was also significantly reduced by a mean of 44% (90% CI −50%, −32%)."	"61"	"decrease"	"percent"	"Co-administration with ketoconazole 400 mg significantly increased rivaroxaban plasma concentrations (Figure 1A). The mean AUC for the actual dose interval (AUCτ) was increased by 158% (90% CI 136%, 182%) and the mean Cmax by 72% (90% CI 61%, 83%) with the combination compared with rivaroxaban alone (Table 2). The mean CL/F was significantly decreased by 61% (90% CI −65%, −58%) with the combination of drugs, and clearance by active renal secretion (CLRS) was also significantly reduced by a mean of 44% (90% CI −50%, −32%)."	"undefined"	"undefined"	"undefined"	"undefined"
"http://localhost/dbmiannotator/PMC3769672.html"	"rivaroxaban _interact with_midazolam "	"Co-administration with midazolam led to an increase in rivaroxaban median tmax from 1.5 h to 4.0 h and slightly decreased the rivaroxaban mean Cmax by 12% compared with rivaroxaban alone, a change that was not statistically significant (90% CI −28%, 7%). Rivaroxaban mean AUC remained almost unchanged."	"DDI clinical trial"	"interact with"	"rivaroxaban "	"midazolam "	"drug1"	""	"12"	"In an open label, three way crossover study, subjects were randomized to receive a single dose of rivaroxaban 20 mg alone, a single dose of midazolam 7.5 mg alone or the combination. All study drugs were given under fasting conditions.
                                                            

                                                            
                                                                A total of 12 subjects were enrolled. Their mean age was 28.5 years (range 19-37 years) and their mean weight was 82.2 ± 11.2 kg. All subjects were included in the analyses of safety and pharmacokinetics."	"20"	"Oral"	"1"	"SD"	"In an open label, three way crossover study, subjects were randomized to receive a single dose of rivaroxaban 20 mg alone, a single dose of midazolam 7.5 mg alone or the combination. All study drugs were given under fasting conditions.
                                                            

                                                            
                                                                A total of 12 subjects were enrolled. Their mean age was 28.5 years (range 19-37 years) and their mean weight was 82.2 ± 11.2 kg. All subjects were included in the analyses of safety and pharmacokinetics."	"7.5"	"Oral"	"1"	"SD"	"In an open label, three way crossover study, subjects were randomized to receive a single dose of rivaroxaban 20 mg alone, a single dose of midazolam 7.5 mg alone or the combination. All study drugs were given under fasting conditions.
                                                            

                                                            
                                                                A total of 12 subjects were enrolled. Their mean age was 28.5 years (range 19-37 years) and their mean weight was 82.2 ± 11.2 kg. All subjects were included in the analyses of safety and pharmacokinetics."	"unchanged"	""	""	". Co-administration with midazolam led to an increase in rivaroxaban median tmax from 1.5 h to 4.0 h and slightly decreased the rivaroxaban mean Cmax by 12% compared with rivaroxaban alone, a change that was not statistically significant (90% CI −28%, 7%). Rivaroxaban mean AUC remained almost unchanged. Co-administration with rivaroxaban slightly decreased the mean AUC of midazolam by 11% compared with midazolam alone, but this was not statistically significant (90% CI −25%, 5%). The mean Cmax was virtually unaffected. Conversely, the mean AUC of α-hydroxy-midazolam remained almost the same with co-administration of rivaroxaban and midazolam compared with midazolam alone, but the mean Cmax was increased by 11%. This change was not statistically significant (90% CI −23%, 59%). The tmax and t1/2 of midazolam and its metabolite remained similar in the presence or absence of rivaroxaban."	"unchanged"	""	""	". Co-administration with midazolam led to an increase in rivaroxaban median tmax from 1.5 h to 4.0 h and slightly decreased the rivaroxaban mean Cmax by 12% compared with rivaroxaban alone, a change that was not statistically significant (90% CI −28%, 7%). Rivaroxaban mean AUC remained almost unchanged. Co-administration with rivaroxaban slightly decreased the mean AUC of midazolam by 11% compared with midazolam alone, but this was not statistically significant (90% CI −25%, 5%). The mean Cmax was virtually unaffected. Conversely, the mean AUC of α-hydroxy-midazolam remained almost the same with co-administration of rivaroxaban and midazolam compared with midazolam alone, but the mean Cmax was increased by 11%. This change was not statistically significant (90% CI −23%, 59%). The tmax and t1/2 of midazolam and its metabolite remained similar in the presence or absence of rivaroxaban."	"undefined"	"undefined"	"undefined"	"undefined"	"unchanged"	""	""	". Co-administration with midazolam led to an increase in rivaroxaban median tmax from 1.5 h to 4.0 h and slightly decreased the rivaroxaban mean Cmax by 12% compared with rivaroxaban alone, a change that was not statistically significant (90% CI −28%, 7%). Rivaroxaban mean AUC remained almost unchanged. Co-administration with rivaroxaban slightly decreased the mean AUC of midazolam by 11% compared with midazolam alone, but this was not statistically significant (90% CI −25%, 5%). The mean Cmax was virtually unaffected. Conversely, the mean AUC of α-hydroxy-midazolam remained almost the same with co-administration of rivaroxaban and midazolam compared with midazolam alone, but the mean Cmax was increased by 11%. This change was not statistically significant (90% CI −23%, 59%). The tmax and t1/2 of midazolam and its metabolite remained similar in the presence or absence of rivaroxaban."
"http://localhost/dbmiannotator/PMC3187007.html"	"Telaprevir_interact with_atorvastatin"	"Telaprevir significantly increased exposure to amlodipine and atorvastatin, consistent with the inhibitory effect of telaprevir on the CYP3A-mediated metabolism of these agents."	"DDI clinical trial"	"interact with"	"Telaprevir"	"atorvastatin"	"drug1"	""	"21"	"Twenty-one healthy male (n = 15) and female (n = 6) volunteers were enrolled at the Covance Clinical Research Unit, Inc., Daytona Beach, FL. The female volunteers were documented not to have childbearing potential. At screening, the volunteers were judged to be in good health on the basis of medical history, physical examination, and routine laboratory measurement results. Volunteers had ended any short-duration courses of prescription medications, herbal medications, or dietary supplements (e.g., St. John's wort, ginkgo biloba, garlic supplements), vitamins, Seville oranges, grapefruit, or grapefruit juice at least 14 days before the administration of the first dose of the study drug. Prescription medications were not administered during the study. Volunteers had stopped over-the-counter medications no less than 2 days before the first administration of the study drug. Occasional use of acetaminophen or ibuprofen was allowed during the study for the treatment of pain. Volunteers could not consume alcohol from 72 h before the first dose of the study drug through the follow-up visit and were nonsmokers (subjects who stopped smoking at least 6 months before screening were considered nonsmokers)."	"375"	"Oral"	"15 days"	"Q8"	"Drugs administered.
                                                        

                                                        
                                                            Telaprevir (375-mg tablets, Patheon, Mississauga, Ontario, Canada) was administered at 750 mg q8h orally in the fed state (30 min after the start of a meal or snack).
                                                        

                                                        
                                                            Amlodipine-atorvastatin (25-mg fixed dose combination tablets containing 5 mg amlodipine and 20 mg atorvastatin; Pfizer Incorporated, New York, NY) was administered orally as a single dose in accordance with the package insert 30 min after the start of breakfast (1). During the study, compliance was assessed on an ongoing basis by counting returned dosage units and reviewing the volunteer logs. All volunteers were ≥90% compliant with the telaprevir dosing regimen, and all volunteers received their scheduled doses of amlodipine-atorvastatin (administered at the clinic)."	"20"	"Oral"	"1 day"	"SD"	"Drugs administered.
                                                        

                                                        
                                                            Telaprevir (375-mg tablets, Patheon, Mississauga, Ontario, Canada) was administered at 750 mg q8h orally in the fed state (30 min after the start of a meal or snack).
                                                        

                                                        
                                                            Amlodipine-atorvastatin (25-mg fixed dose combination tablets containing 5 mg amlodipine and 20 mg atorvastatin; Pfizer Incorporated, New York, NY) was administered orally as a single dose in accordance with the package insert 30 min after the start of breakfast (1). During the study, compliance was assessed on an ongoing basis by counting returned dosage units and reviewing the volunteer logs. All volunteers were ≥90% compliant with the telaprevir dosing regimen, and all volunteers received their scheduled doses of amlodipine-atorvastatin (administered at the clinic)."	"7.88"	"increase"	"fold"	"Based on the ratio of the LS means, the mean Cmax and the AUC0-∞ were markedly increased 10.6-fold and 7.88-fold, respectively, by the coadministration of telaprevir (Table 1). The mean apparent clearance (CL/F) decreased from 685 liters/h to 83.8 liters/h. The mean (SD) t1/2 decreased from 9.44 (2.64) h to 6.75 (1.55) h with telaprevir coadministration; the difference in t1/2 was not statistically significant."	"10.6"	"increase"	"fold"	"Based on the ratio of the LS means, the mean Cmax and the AUC0-∞ were markedly increased 10.6-fold and 7.88-fold, respectively, by the coadministration of telaprevir (Table 1). The mean apparent clearance (CL/F) decreased from 685 liters/h to 83.8 liters/h. The mean (SD) t1/2 decreased from 9.44 (2.64) h to 6.75 (1.55) h with telaprevir coadministration; the difference in t1/2 was not statistically significant."	"87"	"decrease"	"percent"	"Based on the ratio of the LS means, the mean Cmax and the AUC0-∞ were markedly increased 10.6-fold and 7.88-fold, respectively, by the coadministration of telaprevir (Table 1). The mean apparent clearance (CL/F) decreased from 685 liters/h to 83.8 liters/h. The mean (SD) t1/2 decreased from 9.44 (2.64) h to 6.75 (1.55) h with telaprevir coadministration; the difference in t1/2 was not statistically significant."	"29"	"decrease"	"percent"	"Based on the ratio of the LS means, the mean Cmax and the AUC0-∞ were markedly increased 10.6-fold and 7.88-fold, respectively, by the coadministration of telaprevir (Table 1). The mean apparent clearance (CL/F) decreased from 685 liters/h to 83.8 liters/h. The mean (SD) t1/2 decreased from 9.44 (2.64) h to 6.75 (1.55) h with telaprevir coadministration; the difference in t1/2 was not statistically significant."
"http://localhost/dbmiannotator/PMC1884190.html"	"ketoconazole_interact with_rosuvastatin"	"The geometric mean (gmean) plasma concentrations of rosuvastatin over time were similar when rosuvastatin was coadministered with ketoconazole and placebo"	"DDI clinical trial"	"interact with"	"ketoconazole"	"rosuvastatin"	"drug1"	""	"14"	"Healthy adult (18-65 years) male volunteers with no clinically relevant conditions identified from their medical history, physical examination, or electrocardiogram (ECG) were included in the trial. Volunteers were excluded if they had any clinically relevant abnormalities in clinical chemistry, haematology, or urinalysis results, or if total bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or creatine kinase were outside the normal reference range at the start of the trial.
                                                        

                                                        
                                                            Fourteen male Caucasian volunteers were enrolled. Their mean (range) age, height, and weight were 24.1 years (21-31), 182.1 cm (170-189), and 73.5 kg (60-83), respectively. Pharmacokinetic data were available from 13 volunteers [one volunteer withdrew due to personal reasons during the washout period following the first dosing period (rosuvastatin + placebo)]. This withdrawal was considered unlikely to have affected interpretation of the trial data."	"400"	"Oral"	"7 days"	"BID"	"Volunteers were randomized to receive daily oral doses of ketoconazole 400 mg (1 × 200-mg tablet every 12 h) or matching placebo (one tablet every 12 h) for 7 days, with a 2-week washout period between dosing periods. On day 4 of each dosing period, volunteers were given a single oral dose of rosuvastatin 80 mg (1 × 80-mg encapsulated tablet) with the morning dose of ketoconazole or placebo."	"80"	"Oral"	"1 day"	"SD"	"Volunteers were randomized to receive daily oral doses of ketoconazole 400 mg (1 × 200-mg tablet every 12 h) or matching placebo (one tablet every 12 h) for 7 days, with a 2-week washout period between dosing periods. On day 4 of each dosing period, volunteers were given a single oral dose of rosuvastatin 80 mg (1 × 80-mg encapsulated tablet) with the morning dose of ketoconazole or placebo."	"unchanged"	""	""	"Table 1
                                                            
                                                            
                                                            
                                                                Summary pharmacokinetic parameters of rosuvastatin, and results of the statistical analysis of the plasma AUC(0,t) and Cmax of rosuvastatin, when coadministered with ketoconazole and placebo"	"unchanged"	""	""	"Table 1
                                                            
                                                            
                                                            
                                                                Summary pharmacokinetic parameters of rosuvastatin, and results of the statistical analysis of the plasma AUC(0,t) and Cmax of rosuvastatin, when coadministered with ketoconazole and placebo"	"unchanged"	""	""	"Table 1
                                                            
                                                            
                                                            
                                                                Summary pharmacokinetic parameters of rosuvastatin, and results of the statistical analysis of the plasma AUC(0,t) and Cmax of rosuvastatin, when coadministered with ketoconazole and placebo"	"unchanged"	""	""	"Table 1
                                                            
                                                            
                                                            
                                                                Summary pharmacokinetic parameters of rosuvastatin, and results of the statistical analysis of the plasma AUC(0,t) and Cmax of rosuvastatin, when coadministered with ketoconazole and placebo"
